
IMC Response to PMPRB Interim Approach Consultation
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
IMC is committed to working with governments and stakeholders to strengthen Canada’s health systems.
IMC relies on trusted data and research to inform our work, and to create useful tools and resources for all stakeholders.
Learn more about IMC, our members, and our commitment to ethics and social responsibility.
Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.
New medicines and vaccines save lives and help make our healthcare system more cost‑effective.
Preventing or curing disease means extending lives, relieving suffering and improving people’s quality of life.
Promoting a robust regulatory protocol means ensuring safe and effective medicines for Canadians.
Supporting sustainable healthcare means we all spend more time enjoying life and being productive.
Innovative Medicines Canada members
High-quality jobs
Yearly economic impact
Patented Medicine Prices Review Board (PMPRB) • July 20, 2022
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
Access to Medicine • July 06, 2022
IMC supports the creation of a Pan Canadian Genomics Strategy (PCGS) to help Canada advance its international leadership and increase capacity in genomics through commercialization and adoption.
Access to Medicine • June 28, 2022
Use this tool to search for brand name drugs to view their current negotiation status.
Access to Medicine • June 28, 2022
Learn more about the negotiation process from the pCPA.
Access to Medicine • February 12, 2022
This policy note characterizes Canada’s current testing infrastructure and its limitations, which include that it hinders current and future patient access to the best available treatments.
Access to Medicine • February 05, 2022
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
Ethics • January 01, 2022
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
Press Release July 06, 2022
Ottawa, July 6, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, acknowledges the amendments to […]
Press Release June 17, 2022
Ottawa, June 17, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, is disappointed by the intellectual […]
Press Release June 15, 2022
Ottawa, June 15, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, acknowledges the release of the […]
Press Release June 10, 2022
Ottawa, June 9, 2022 – The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework […]
Press Release June 06, 2022
Ottawa, June 6, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, applauds the Quebec government on […]
Press Release May 30, 2022
Ottawa, May 30, 2022 – Innovative Medicines Canada (IMC) is pleased to announce Alok Kanti, President and Chief Executive Officer of […]
Press Release May 25, 2022
Nominate a remarkable individual who is making a difference in health sciences by June 22. OTTAWA, ON, May 25, 2022 […]
Press Release May 12, 2022
Ottawa, May 12, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, welcomes Quebec’s new Life […]
Informative content to keep you up to date on the most pressing issues facing our industry.